Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
A thrombopoietin receptor agonist that increases platelet production. Indicated in the treatment of immune thrombopenic purpura, severe aplastic anemia and hepatitis C.
Administered orally once a day.
Since the last update we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data (high percentage of protein binding and very low pKa) makes transfer to milk in significant amounts unlikely.
Its low oral bioavailability impedes transfer from breastmilk to infant plasma, except in premature infants and the immediate neonatal period when there may be greater intestinal permeability.
In addition, eltrombopag forms chelates with polyvalent ions such as calcium, which significantly reduces the drug’s possible absorption by the infant (EMA 2015)
Its use is authorized in Pediatrics from one year of age (EMA 2015).